SCHEMBL29637741

SCHEMBL29637741

COc1ccc(C(N)=O)nc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.56
SIRT6 Q8N6T7 1/20 0.55
PARP10 Q53GL7 2/20 0.52
PARP1 P09874 2/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
PARP2 Q9UGN5 1/20 0.52
PARP4 Q9UKK3 1/20 0.52
NNMT P40261 2/20 0.52
KMT2A Q03164 1/20 0.49
HPGDS O60760 1/20 0.47
PDE10A Q9Y233 1/20 0.46
DRD3 P35462 1/20 0.46
MAP4K4 O95819 1/20 0.45
PDE4A P27815 1/20 0.45
PDE4B Q07343 1/20 0.45
PDE4C Q08493 1/20 0.45
PDE4D Q08499 1/20 0.45
P4HTM Q9NXG6 1/20 0.44
KDM4E B2RXH2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3133220 1.00 APP (0.56) APPSIRT6PARP10PARP1CA1
Hydrochloric Acid SCHEMBL31539646 0.98 APP (0.55) APPSIRT6PARP10PARP1CA1
SCHEMBL18496090 0.87 NNMT (0.49) APPSIRT6PARP10PARP1CA1
SCHEMBL287134 0.82 P4HTM (0.60) CA1CA2KMT2ADRD3P4HTM
SCHEMBL2187078 0.82 DRD3 (0.47) APPCA1CA2DRD3P4HTM
SCHEMBL10157712 0.82 PRSS1 (0.53) APPSIRT6PARP10PARP1CA1
SCHEMBL31424227 0.82 PRSS1 (0.53) APPSIRT6PARP10PARP1CA1
SCHEMBL6302880 0.81 PARP10 (0.58) APPSIRT6PARP10KMT2AP4HTM
SCHEMBL29889518 0.81 CHEK2 (0.48) APPSIRT6PARP10NNMTKMT2A
SCHEMBL16011699 0.81 P4HTM (0.59) CA1CA2KMT2ADRD3P4HTM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119569647-A Buried material compound and application thereof in perovskite battery 厦门紫金新能源新材料科技有限公司 2025-03-07 CN claimed
CN-122055155-A Percutaneous absorption composition 美德阿利克斯株式会社 2026-05-15 CN disclosed
CN-122055155-A Percutaneous absorption composition 美德阿利克斯株式会社 2026-05-15 CN disclosed
CN-119569647-A Buried material compound and application thereof in perovskite battery 厦门紫金新能源新材料科技有限公司 2025-03-07 CN disclosed
WO-2024206939-A2 SARS-COV-2 ENTRY INHIBITORS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2024-10-03 WO disclosed
CN-116547282-A Heterocyclic compounds and their use for the treatment of helminth infections and diseases 新基公司 2023-08-04 CN disclosed
CN-115210227-A Heterobifunctional molecules as TEAD inhibitors 基因泰克公司 2022-10-18 CN disclosed
US-20220202815-A1 TREATMENT OF CANCER MINGSIGHT PHARMACEUTICALS, INC. 2022-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220202815-A1 TREATMENT OF CANCER PRKACB, PRKDC, PRKCH APP 4807/4885SIRT6 2981/4885PARP10 1896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.